Precision medicine in newly diagnosed breast cancer

MyPathway study: a novel precision oncology multiple basket trial

Editor's Choice for June 2018

CDK6 a transcriptional regulator in AML

ASCO 2018 conference round up

Results from the phase I ICONIC trial

Design and interim safety analysis of GeparX trial

What does progression-free survival mean for breast cancer patients?

Finding appropriate doses for HER2 positive breast cancers

Results from the LILAC study of ABP 980 with trastuzumab for HER2 early breast cancer

Most breast cancer patients could avoid chemo with use of genetic testing

Comment: Genetic testing of early breast tumours could allow patients to go without chemo